Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

April 10, 2025

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

March 21, 2025

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.